Nadine Houédé

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon, Charles G. Drake, H. I. Scher et al. · The Lancet Oncology · 2014 · 1.5K citations · Full text

Urology, Oncology, Docetaxel Chemotherapy +9

Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer

Pierre Soubeyran, Marianne Fonck, C. Blanc-Bisson et al. · Journal of Clinical Oncology · 2012 · 424 citations · Full text

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

Yohann Loriot, Nobuaki Matsubara, Se Hoon Park et al. · New England Journal of Medicine · 2023 · 255 citations

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

Matthew R. Smith, Johann S. de Bono, Cora N. Sternberg et al. · Journal of Clinical Oncology · 2016 · 244 citations

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Karim Fizazi, Laura Faivre, F. Lesaunier et al. · The Lancet Oncology · 2015 · 236 citations

Urology, Getug 12, Genitourinary Cancer +8